Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1240
Name leukemia
Definition A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.
Source DiseaseOntology.org
Alt Ids DOID:9145
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FLT3 act mut Pexidartinib leukemia sensitive detail...
NRAS mutant Trametinib leukemia predicted - sensitive detail...
KMT2A rearrange Doxorubicin + I-CBP112 leukemia predicted - sensitive detail...
KMT2A rearrange I-CBP112 + JQ1 leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 F691L Pexidartinib leukemia sensitive detail...
FLT3 exon 14 ins Pexidartinib leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Pexidartinib leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 M837_D839delinsGRH Pexidartinib leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 S652G Pexidartinib leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835H Pexidartinib leukemia resistant detail...
TP53 mutant RG7112 leukemia decreased response detail...
FLT3 exon 14 ins E6201 leukemia sensitive detail...
FLT3 D835G E6201 leukemia sensitive detail...
FLT3 D835Y E6201 leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L E6201 leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C E6201 leukemia sensitive detail...
FLT3 exon 14 ins FLT3 N676D FLT3 Y842C E6201 leukemia sensitive detail...
KIT N822K Ponatinib leukemia sensitive detail...
PIK3CA E545K LY3023414 leukemia sensitive detail...
FGFR1 rearrange AZD4547 leukemia sensitive detail...
ALK negative CEP-28122 leukemia resistant detail...
NRAS mutant Alpelisib + Binimetinib leukemia sensitive detail...
NRAS mutant Belvarafenib leukemia sensitive detail...
FLT3 exon 14 ins GMI-1359 leukemia predicted - sensitive detail...
FLT3 exon 14 ins GMI-1359 + Sorafenib leukemia predicted - sensitive detail...
FLT3 exon 14 ins FN-1501 leukemia sensitive detail...
JAK2 V617F LGH447 + Ribociclib + Ruxolitinib leukemia predicted - sensitive detail...
TET2 loss TETi76 leukemia sensitive detail...
IDH1 R132C TETi76 leukemia sensitive detail...
IDH2 R140Q TETi76 leukemia sensitive detail...
VHL Y112C ARV-771 leukemia resistant detail...
VHL W117* ARV-771 leukemia resistant detail...
VHL S111R ARV-771 leukemia resistant detail...
VHL V166F ARV-771 leukemia resistant detail...
VHL S139fs ARV-771 leukemia resistant detail...
IDH2 R140Q IDH2 Q316E Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 I319M Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 H348Q Enasidenib leukemia predicted - resistant detail...
IDH1 R132H IDH1 S280F Ivosidenib leukemia predicted - resistant detail...
IDH1 R132H IDH1 H315D Ivosidenib leukemia resistant detail...
IDH1 R132H IDH1 H315D Vorasidenib leukemia predicted - resistant detail...
IDH1 R132H IDH1 H315D IDH305 leukemia predicted - resistant detail...
IDH1 R132H IDH1 H315D BAY1436032 leukemia predicted - resistant detail...
IDH1 R132H IDH1 T313I Ivosidenib leukemia resistant detail...
IDH1 R132H IDH1 T313I Vorasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 E343V Enasidenib leukemia resistant detail...
IDH2 R140Q IDH2 A347T Enasidenib leukemia resistant detail...
IDH2 R140Q IDH2 E343V Vorasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 A347T Vorasidenib leukemia predicted - resistant detail...
IDH2 N136S IDH2 R140Q Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 E345G Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 V351I Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 T352A Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 R353H Enasidenib leukemia predicted - resistant detail...
IDH2 R140Q IDH2 L449V Enasidenib leukemia predicted - sensitive detail...
IDH2 R140Q IDH2 G450S Enasidenib leukemia predicted - sensitive detail...
IDH1 R132H IDH1 T313I IDH305 leukemia predicted - resistant detail...
IDH1 R132H IDH1 T313I BAY1436032 leukemia predicted - resistant detail...
IDH1 R132H IDH1 L409V Ivosidenib leukemia predicted - sensitive detail...
IDH1 R132H IDH1 A410T Ivosidenib leukemia predicted - sensitive detail...
NRAS G12C Sotorasib leukemia predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00620633 Phase I ATA520 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation Completed USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01396499 Phase I Buparlisib Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias Completed USA 0
NCT01703572 Phase I Brontictuzumab A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Completed USA 0
NCT01751425 Phase II Ruxolitinib Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Terminated USA 0
NCT02028455 Phase Ib/II Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Active, not recruiting USA 0
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting USA 0
NCT02499861 Phase Ib/II Decitabine + Genistein Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies Completed CAN 0
NCT02512926 Phase I Cyclophosphamide Carfilzomib Etoposide Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Completed USA | CAN 0
NCT02569476 Phase I Obinutuzumab + Zanubrutinib BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies Completed USA | AUS 1
NCT02786485 Phase I Rimiducid Rivogenlecleucel Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn 0
NCT02932280 Phase Ib/II Neratinib Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Recruiting USA | CAN 0
NCT03186118 Phase I Autologous CD19t T-APC Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia Active, not recruiting USA 0
NCT03229200 FDA approved Ibrutinib Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation USA | ITA | GBR | FRA | ESP | CAN | AUS 10
NCT03884829 Phase I CYC140 A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Recruiting USA 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting ITA | GBR | FRA | ESP | DEU | BEL 3
NCT04526795 Phase I Cytarabine + Fludarabine + Pegcrisantaspase Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Active, not recruiting USA 0
NCT04571138 Phase Ib/II SCRI-CAR22v2 A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma Recruiting USA 0
NCT04881240 Phase I CD19-CAR(Mem) T-cells + Cyclophosphamide + Fludarabine + Mesna Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia Recruiting USA 0